Company Overview

Diagnamed Holdings Corp. is a publicly traded biotechnology and life sciences company focused on the research and development of psychedelic-based therapies for neurological disorders, addiction, and mental health conditions. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on developing novel drug candidates derived from psychoactive compounds under regulated medical frameworks.

The company’s primary business activity centers on early-stage drug discovery and preclinical development rather than commercialized pharmaceutical sales, meaning it does not currently generate material operating revenue. Diagnamed’s strategic positioning is based on its focus on non-hallucinogenic or controlled-dose applications of psychedelic compounds, particularly ibogaine-related therapies, which it positions as having potential advantages in safety and regulatory acceptance. Diagnamed was founded in Canada and evolved from a broader life sciences focus into a more specialized psychedelic medicine developer as scientific and regulatory interest in the sector increased during the late 2010s.

Business Operations

Diagnamed’s operations are primarily structured around research and development activities, including compound formulation, preclinical testing, and intellectual property development related to psychedelic-derived therapeutics. The company does not report traditional operating segments; instead, its business is managed as a single reporting unit focused on drug development and licensing potential.

Operations are conducted through corporate-controlled research programs and external collaborations rather than owned manufacturing or clinical infrastructure. The company relies on third-party laboratories, academic relationships, and contract research organizations for testing and validation. Public disclosures do not conclusively identify material revenue-generating subsidiaries or joint ventures, and no commercial-stage products or approved therapies have been reported. Data inconclusive based on available public sources regarding long-term contractual partnerships.

Strategic Position & Investments

Diagnamed’s strategy is centered on advancing proprietary psychedelic-based compounds toward clinical relevance, with the longer-term objective of licensing, partnering, or acquisition by larger pharmaceutical entities. Growth initiatives have historically focused on expanding intellectual property portfolios and exploring therapeutic indications related to addiction, traumatic brain injury, and neurodegenerative diseases.

The company has reported investments primarily in internal research programs rather than large-scale acquisitions. Public filings indicate an emphasis on capital preservation and targeted R&D spending consistent with an early-stage biotech model. While Diagnamed has announced exploration of emerging psychedelic medicine technologies, the commercial viability and developmental timelines of these initiatives remain uncertain. Data inconclusive based on available public sources regarding late-stage clinical progression.

Geographic Footprint

Diagnamed Holdings Corp. is headquartered in Canada, with its corporate, regulatory, and investor relations activities primarily managed domestically. Its common shares trade in Canadian and U.S. over-the-counter markets, giving it access to North American capital markets.

Operationally, the company’s influence is international through research collaborations and scientific engagement rather than owned facilities. Its development activities may involve service providers or research institutions in North America and Europe, but no permanent international offices or manufacturing sites have been conclusively disclosed. Data inconclusive based on available public sources regarding sustained operational presence outside Canada.

Leadership & Governance

Diagnamed is led by executives with experience in life sciences, capital markets, and early-stage biotechnology development. The leadership team emphasizes disciplined capital management, regulatory alignment, and long-term value creation through intellectual property development rather than near-term commercialization.

Key executives include:

• Mike Witjes – Chief Executive Officer
• Darren M. Schaffer – Chairman of the Board
• Mark E. Rutledge – Chief Financial Officer

Public disclosures provide limited detail on broader executive depth or formalized leadership philosophy statements. Governance practices follow Canadian public company standards, but detailed committee structures and succession planning disclosures are limited. Data inconclusive based on available public sources regarding expanded executive leadership beyond those listed.